-
Something wrong with this record ?
European Groundshot-addressing Europe's cancer research challenges: a Lancet Oncology Commission
M. Lawler, L. Davies, S. Oberst, K. Oliver, A. Eggermont, A. Schmutz, C. La Vecchia, C. Allemani, Y. Lievens, P. Naredi, T. Cufer, A. Aggarwal, M. Aapro, K. Apostolidis, AM. Baird, F. Cardoso, A. Charalambous, MP. Coleman, A. Costa, M. Crul, CL....
Language English Country England, Great Britain
Document type Journal Article, Review, Research Support, Non-U.S. Gov't
Grant support
Medical Research Council - United Kingdom
Cancer Research UK - United Kingdom
NLK
ProQuest Central
from 2000-09-01 to 2 months ago
Nursing & Allied Health Database (ProQuest)
from 2000-09-01 to 2 months ago
Health & Medicine (ProQuest)
from 2000-09-01 to 2 months ago
Public Health Database (ProQuest)
from 2000-09-01 to 2 months ago
- MeSH
- COVID-19 * epidemiology MeSH
- Humans MeSH
- Neoplasms * diagnosis epidemiology therapy MeSH
- Pandemics MeSH
- Health Services Research MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Geographicals
- Europe MeSH
- Europe, Eastern MeSH
Cancer research is a crucial pillar for countries to deliver more affordable, higher quality, and more equitable cancer care. Patients treated in research-active hospitals have better outcomes than patients who are not treated in these settings. However, cancer in Europe is at a crossroads. Cancer was already a leading cause of premature death before the COVID-19 pandemic, and the disastrous effects of the pandemic on early diagnosis and treatment will probably set back cancer outcomes in Europe by almost a decade. Recognising the pivotal importance of research not just to mitigate the pandemic today, but to build better European cancer services and systems for patients tomorrow, the Lancet Oncology European Groundshot Commission on cancer research brings together a wide range of experts, together with detailed new data on cancer research activity across Europe during the past 12 years. We have deployed this knowledge to help inform Europe's Beating Cancer Plan and the EU Cancer Mission, and to set out an evidence-driven, patient-centred cancer research roadmap for Europe. The high-resolution cancer research data we have generated show current activities, captured through different metrics, including by region, disease burden, research domain, and effect on outcomes. We have also included granular data on research collaboration, gender of researchers, and research funding. The inclusion of granular data has facilitated the identification of areas that are perhaps overemphasised in current cancer research in Europe, while also highlighting domains that are underserved. Our detailed data emphasise the need for more information-driven and data-driven cancer research strategies and planning going forward. A particular focus must be on central and eastern Europe, because our findings emphasise the widening gap in cancer research activity, and capacity and outcomes, compared with the rest of Europe. Citizens and patients, no matter where they are, must benefit from advances in cancer research. This Commission also highlights that the narrow focus on discovery science and biopharmaceutical research in Europe needs to be widened to include such areas as prevention and early diagnosis; treatment modalities such as radiotherapy and surgery; and a larger concentration on developing a research and innovation strategy for the 20 million Europeans living beyond a cancer diagnosis. Our data highlight the important role of comprehensive cancer centres in driving the European cancer research agenda. Crucial to a functioning cancer research strategy and its translation into patient benefit is the need for a greater emphasis on health policy and systems research, including implementation science, so that the innovative technological outputs from cancer research have a clear pathway to delivery. This European cancer research Commission has identified 12 key recommendations within a call to action to reimagine cancer research and its implementation in Europe. We hope this call to action will help to achieve our ambitious 70:35 target: 70% average 10-year survival for all European cancer patients by 2035.
Amsterdam UMC Amsterdam Netherlands
Belgian Royal Academy of Medicine Brussels Belgium
Cancer Center University of Navarra Madrid Spain
Cancer Survival Group London School of Hygiene and Tropical Medicine London UK
Candiolo Cancer Institute FPO IRCCS Candiolo Italy
Centre for Innovation in Medicine and Kol Medical Media Bucharest Romania
Champalimaud Clinical Center Champalimaud Foundation Lisbon Portugal
Department of Clinical Sciences and Community Health Università degli Studi di Milano Milan Italy
Department of Nursing Cyprus University of Technology Limassol Cyprus
Department of Oncology University of Turin Turin Italy
Department of Oncology University of Turku Turku Finland
Department of Radiation Oncology Ghent University and Ghent University Hospital Ghent Belgium
Diagnoza leukemie Prague Czech Republic
EuropaColon Slovenia Ljubljana Slovenia
European Cancer Organisation Brussels Brussels Belgium
European Cancer Organisation Patient Advisory Committee Brussels Belgium
European Cancer Organisation Patient Advisory Committee Europa Donna Istanbul Türkiye
European Cancer Patient Coalition Brussels Belgium
European School of Oncology Milan Italy
Faculty of Medicine and Cancer Institute Hacettepe University Ankara Türkiye
Faculty of Medicine University of Ljubljana Ljubljana Slovenia
Faculty of Medicine Utrecht University Medical Center Utrecht Netherlands
Faculty of Sociology and Social Work Babeș Bolyai University Cluj Napoca Romania
Genolier Cancer Center Genolier Switzerland
Guy's and St Thomas' NHS Foundation Trust London UK
Hellenic Cancer Federation Athens Greece
Institute of Cancer Policy King's College London London UK
Institute of Cancer Policy School of Cancer Sciences Kings College London London UK
International Agency for Cancer Research Lyon France
International Agency for Research on Cancer Lyon France
International Brain Tumour Alliance Tadworth UK
International Cancer Research Partnership International House Cardiff UK
International Neuroendocrine Cancer Alliance Boston MA USA
Lung Cancer Europe Bern Switzerland
Maria Skłodowska Curie National Research Institute of Oncology Warsaw Poland
Medical University of Gdańsk Gdańsk Poland
Melanoma Patient Network Europe Brussels Belgium
Netherlands Comprehensive Cancer Organisation Utrecht Netherlands
Organisation of European Cancer Institutes Brussels Belgium
Patvocates and CML Advocates Network Leukaemie Online Munich Germany
Princess Máxima Centrum Utrecht Netherlands
School of Healthcare Sciences Cardiff University Cardiff UK
School of Medicine University of Leeds Leeds UK
Stockholm School of Economics Stockholm Sweden
Trinity Translational Medicine Institute Trinity College Dublin Dublin Ireland
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23004765
- 003
- CZ-PrNML
- 005
- 20230425171716.0
- 007
- ta
- 008
- 230418s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S1470-2045(22)00540-X $2 doi
- 035 __
- $a (PubMed)36400101
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Lawler, Mark $u Patrick G Johnston Centre for Cancer Research, Faculty of Medicine, Health and Life Sciences, Queen's University Belfast, Belfast, UK. Electronic address: mark.lawler@qub.ac.uk
- 245 10
- $a European Groundshot-addressing Europe's cancer research challenges: a Lancet Oncology Commission / $c M. Lawler, L. Davies, S. Oberst, K. Oliver, A. Eggermont, A. Schmutz, C. La Vecchia, C. Allemani, Y. Lievens, P. Naredi, T. Cufer, A. Aggarwal, M. Aapro, K. Apostolidis, AM. Baird, F. Cardoso, A. Charalambous, MP. Coleman, A. Costa, M. Crul, CL. Dégi, F. Di Nicolantonio, S. Erdem, M. Geanta, J. Geissler, J. Jassem, B. Jagielska, B. Jonsson, D. Kelly, O. Kelm, T. Kolarova, T. Kutluk, G. Lewison, F. Meunier, J. Pelouchova, T. Philip, R. Price, B. Rau, IT. Rubio, P. Selby, M. Južnič Sotlar, G. Spurrier-Bernard, JC. van Hoeve, E. Vrdoljak, W. Westerhuis, U. Wojciechowska, R. Sullivan
- 520 9_
- $a Cancer research is a crucial pillar for countries to deliver more affordable, higher quality, and more equitable cancer care. Patients treated in research-active hospitals have better outcomes than patients who are not treated in these settings. However, cancer in Europe is at a crossroads. Cancer was already a leading cause of premature death before the COVID-19 pandemic, and the disastrous effects of the pandemic on early diagnosis and treatment will probably set back cancer outcomes in Europe by almost a decade. Recognising the pivotal importance of research not just to mitigate the pandemic today, but to build better European cancer services and systems for patients tomorrow, the Lancet Oncology European Groundshot Commission on cancer research brings together a wide range of experts, together with detailed new data on cancer research activity across Europe during the past 12 years. We have deployed this knowledge to help inform Europe's Beating Cancer Plan and the EU Cancer Mission, and to set out an evidence-driven, patient-centred cancer research roadmap for Europe. The high-resolution cancer research data we have generated show current activities, captured through different metrics, including by region, disease burden, research domain, and effect on outcomes. We have also included granular data on research collaboration, gender of researchers, and research funding. The inclusion of granular data has facilitated the identification of areas that are perhaps overemphasised in current cancer research in Europe, while also highlighting domains that are underserved. Our detailed data emphasise the need for more information-driven and data-driven cancer research strategies and planning going forward. A particular focus must be on central and eastern Europe, because our findings emphasise the widening gap in cancer research activity, and capacity and outcomes, compared with the rest of Europe. Citizens and patients, no matter where they are, must benefit from advances in cancer research. This Commission also highlights that the narrow focus on discovery science and biopharmaceutical research in Europe needs to be widened to include such areas as prevention and early diagnosis; treatment modalities such as radiotherapy and surgery; and a larger concentration on developing a research and innovation strategy for the 20 million Europeans living beyond a cancer diagnosis. Our data highlight the important role of comprehensive cancer centres in driving the European cancer research agenda. Crucial to a functioning cancer research strategy and its translation into patient benefit is the need for a greater emphasis on health policy and systems research, including implementation science, so that the innovative technological outputs from cancer research have a clear pathway to delivery. This European cancer research Commission has identified 12 key recommendations within a call to action to reimagine cancer research and its implementation in Europe. We hope this call to action will help to achieve our ambitious 70:35 target: 70% average 10-year survival for all European cancer patients by 2035.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a pandemie $7 D058873
- 650 12
- $a COVID-19 $x epidemiologie $7 D000086382
- 650 _2
- $a výzkum zdravotnických služeb $7 D006302
- 650 12
- $a nádory $x diagnóza $x epidemiologie $x terapie $7 D009369
- 651 _2
- $a Evropa $x epidemiologie $7 D005060
- 651 _2
- $a východní Evropa $7 D005061
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Davies, Lynne $u International Cancer Research Partnership, International House, Cardiff, UK
- 700 1_
- $a Oberst, Simon $u Organisation of European Cancer Institutes, Brussels, Belgium
- 700 1_
- $a Oliver, Kathy $u International Brain Tumour Alliance, Tadworth, UK; European Cancer Organisation Patient Advisory Committee, Brussels, Belgium
- 700 1_
- $a Eggermont, Alexander $u Faculty of Medicine, Utrecht University Medical Center, Utrecht, Netherlands; Princess Máxima Centrum, Utrecht, Netherlands
- 700 1_
- $a Schmutz, Anna $u International Agency for Cancer Research, Lyon, France
- 700 1_
- $a La Vecchia, Carlo $u Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy
- 700 1_
- $a Allemani, Claudia $u Cancer Survival Group, London School of Hygiene & Tropical Medicine, London, UK
- 700 1_
- $a Lievens, Yolande $u Department of Radiation Oncology, Ghent University and Ghent University Hospital, Ghent, Belgium
- 700 1_
- $a Naredi, Peter $u Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden
- 700 1_
- $a Cufer, Tanja $u Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- 700 1_
- $a Aggarwal, Ajay $u Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK; Institute of Cancer Policy, King's College London, London, UK; Guy's and St Thomas' NHS Foundation Trust, London, UK
- 700 1_
- $a Aapro, Matti $u Genolier Cancer Center, Genolier, Switzerland
- 700 1_
- $a Apostolidis, Kathi $u Hellenic Cancer Federation, Athens, Greece; European Cancer Patient Coalition, Brussels, Belgium
- 700 1_
- $a Baird, Anne-Marie $u Lung Cancer Europe, Bern, Switzerland; Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland
- 700 1_
- $a Cardoso, Fatima $u Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
- 700 1_
- $a Charalambous, Andreas $u European Cancer Organisation Brussels, Brussels, Belgium; Department of Nursing, Cyprus University of Technology, Limassol, Cyprus; Department of Oncology, University of Turku, Turku, Finland
- 700 1_
- $a Coleman, Michel P $u Cancer Survival Group, London School of Hygiene & Tropical Medicine, London, UK
- 700 1_
- $a Costa, Alberto $u European School of Oncology, Milan, Italy
- 700 1_
- $a Crul, Mirjam $u Amsterdam UMC, Amsterdam, Netherlands
- 700 1_
- $a Dégi, Csaba L $u Faculty of Sociology and Social Work, Babeș-Bolyai University, Cluj-Napoca, Romania
- 700 1_
- $a Di Nicolantonio, Federica $u Department of Oncology, University of Turin, Turin, Italy; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
- 700 1_
- $a Erdem, Sema $u European Cancer Organisation Patient Advisory Committee, Europa Donna, Istanbul, Türkiye
- 700 1_
- $a Geanta, Marius $u Centre for Innovation in Medicine and Kol Medical Media, Bucharest, Romania
- 700 1_
- $a Geissler, Jan $u Patvocates and CML Advocates Network, Leukaemie-Online (LeukaNET), Munich, Germany
- 700 1_
- $a Jassem, Jacek $u Medical University of Gdańsk, Gdańsk, Poland
- 700 1_
- $a Jagielska, Beata $u Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
- 700 1_
- $a Jonsson, Bengt $u Stockholm School of Economics, Stockholm, Sweden
- 700 1_
- $a Kelly, Daniel $u School of Healthcare Sciences, Cardiff University, Cardiff, UK
- 700 1_
- $a Kelm, Olaf $u International Agency for Research on Cancer, Lyon, France
- 700 1_
- $a Kolarova, Teodora $u International Neuroendocrine Cancer Alliance, Boston, MA, USA
- 700 1_
- $a Kutluk, Tezer $u Faculty of Medicine & Cancer Institute, Hacettepe University, Ankara, Türkiye
- 700 1_
- $a Lewison, Grant $u Institute of Cancer Policy, School of Cancer Sciences, Kings College London, London, UK
- 700 1_
- $a Meunier, Françoise $u Belgian Royal Academy of Medicine, Brussels, Belgium
- 700 1_
- $a Pelouchova, Jana $u Diagnoza leukemie, Prague, Czech Republic
- 700 1_
- $a Philip, Thierry $u Organisation of European Cancer Institutes, Brussels, Belgium; Institut Curie, Paris, France
- 700 1_
- $a Price, Richard $u European Cancer Organisation Brussels, Brussels, Belgium
- 700 1_
- $a Rau, Beate $u Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
- 700 1_
- $a Rubio, Isabel T $u Cancer Center, University of Navarra, Madrid, Spain
- 700 1_
- $a Selby, Peter $u School of Medicine, University of Leeds, Leeds, UK
- 700 1_
- $a Južnič Sotlar, Maja $u EuropaColon Slovenia, Ljubljana, Slovenia
- 700 1_
- $a Spurrier-Bernard, Gilliosa $u Melanoma Patient Network Europe, Brussels, Belgium
- 700 1_
- $a van Hoeve, Jolanda C $u Organisation of European Cancer Institutes, Brussels, Belgium; Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands
- 700 1_
- $a Vrdoljak, Eduard $u Department of Oncology, University Hospital Center Split, School of Medicine, University of Split, Split, Croatia
- 700 1_
- $a Westerhuis, Willien $u Organisation of European Cancer Institutes, Brussels, Belgium; Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands
- 700 1_
- $a Wojciechowska, Urszula $u Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
- 700 1_
- $a Sullivan, Richard $u Institute of Cancer Policy, School of Cancer Sciences, Kings College London, London, UK
- 773 0_
- $w MED00011558 $t The Lancet. Oncology $x 1474-5488 $g Roč. 24, č. 1 (2023), s. e11-e56
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36400101 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425171712 $b ABA008
- 999 __
- $a ok $b bmc $g 1925074 $s 1190974
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 24 $c 1 $d e11-e56 $e 20221116 $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
- GRA __
- $p Medical Research Council $2 United Kingdom
- GRA __
- $p Cancer Research UK $2 United Kingdom
- LZP __
- $a Pubmed-20230418
